Establishment Labs Excited to Present at J.P. Morgan Conference
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a pioneering force in the realm of women's health and wellness, has announced its participation in a highly anticipated event. The company is set to present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference. This influential gathering promises to bring together industry leaders and innovators focused on advancing medical technologies.
Leadership Team to Take the Stage
Leading the presentation will be Juan José Chacón-Quirós, the passionate Founder and CEO of Establishment Labs, along with Raj Denhoy, the accomplished Chief Financial Officer. The duo is scheduled to take the stage to share insights into the company's groundbreaking advancements in breast aesthetics and reconstruction.
Innovation in Women's Health
Establishment Labs prides itself on its commitment to improving women's health through innovative solutions. With a diverse portfolio of Femtech products designed to enhance breast health, their offerings stand out in the medical technology sector. The introduction of the Motiva® devices has significantly evolved safety and satisfaction standards in over 85 countries.
Investing in the Future
The live webcast of their presentation will be accessible to the public via the Establishment Labs investor relations site. This offers a unique opportunity for stakeholders and interested parties to engage with the company's vision and mission. An archived version will also be available post-event, ensuring that the insights shared reach an even wider audience.
Establishment Labs: A Closer Look
As a global leader in medical technology, Establishment Labs focuses on harnessing the power of science and engineering for the betterment of women's health. The company has delivered nearly four million Motiva® implants since its inception, setting a new safety benchmark for patients and surgeons alike. The Motiva Flora® tissue expander is another significant innovation, improving post-cancer reconstruction outcomes and boasting unique regulatory-approved features.
Commitment to Quality and Safety
Establishment Labs is not only committed to innovation but also to maintaining the highest standards of quality. With two manufacturing facilities located in Costa Rica, the company complies with rigorous international regulatory standards, including ISO13485:2016 and FDA regulations. This commitment ensures that their products not only meet but exceed expectations in safety and efficacy.
Looking Ahead
With over 200 patent applications in various stages across 20 families, Establishment Labs showcases a deep commitment to research and development. Their dedication is further complemented by over 100 peer-reviewed scientific studies that validate their innovations in the field of breast health. As the company prepares for the forthcoming conference, it remains optimistic about the future of women's health technology and its continuing role in the global healthcare landscape.
Frequently Asked Questions
What is the purpose of the J.P. Morgan Healthcare Conference?
The J.P. Morgan Healthcare Conference serves as a platform for leading companies in the healthcare industry to showcase their innovations and connect with investors and stakeholders.
Who will represent Establishment Labs at the conference?
Juan José Chacón-Quirós, CEO, and Raj Denhoy, CFO, will represent Establishment Labs at the conference.
What are some key products from Establishment Labs?
Key products include the Motiva® silicone implants, Motiva Flora® tissue expander, and Mia Femtech™, all aimed at enhancing women's health.
Where can I watch the presentation?
The presentation will be available via a live webcast on the Establishment Labs investor relations website, with an archived version accessible after the event.
How does Establishment Labs ensure product safety?
Establishment Labs maintains high product safety standards by adhering to ISO13485:2016 and FDA regulations, ensuring quality manufacturing processes.
